Form 4: Pacira BioSciences CAO Sells Shares

Pacira BioSciences' Chief Administrative Officer, Kristen Williams, reported the sale of company common stock, including shares withheld for tax obligations and shares sold under a 10b5-1 plan.

Summary

• Kristen Williams, Chief Administrative Officer of Pacira BioSciences, Inc. (PCRX), reported transactions involving company common stock.
• On January 30, 2026, 17,134 shares were disposed of at $20.54 per share to cover tax withholding obligations related to a restricted stock unit award vesting.
• On February 2, 2026, an additional 13,137 shares were sold at $20.53 per share under a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Kristen Williams beneficially owns 131,303 shares of Pacira BioSciences common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While insider selling can sometimes be perceived negatively, a significant portion was for tax obligations, and the remainder was under a pre-planned 10b5-1 program, which mitigates concerns about opportunistic selling.

Positives

• The sale of 13,137 shares was executed pursuant to a Rule 10b5-1 trading plan, indicating a pre-scheduled transaction rather than an opportunistic sale.

Negatives

• Insider selling, even when pre-planned or for tax purposes, can sometimes be perceived negatively by the market, potentially signaling a lack of conviction or a need for liquidity.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Management Comments

• The sale reported was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under pre-arranged 10b5-1 plans, are common for executives managing their personal portfolios and liquidity, and do not necessarily reflect a change in their outlook on the company's future performance. Such filings are standard regulatory disclosures across the biotechnology and pharmaceutical sectors.

Comparison to Industry Standards

• Form 4 filings are standard regulatory disclosures for insider transactions across all publicly traded companies in the U.S. The use of a 10b5-1 plan aligns with best practices for executives to avoid accusations of trading on material non-public information, a practice widely adopted by executives at companies like Pfizer, Johnson & Johnson, and Merck to manage their equity holdings systematically.

Stakeholder Impact

• Shareholders: May observe a slight increase in shares available on the market, but the overall impact is minimal given the volume relative to total outstanding shares. No direct impact on company operations or strategy is indicated.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

The reported transactions are routine insider sales, primarily for tax purposes and under a pre-established 10b5-1 plan. They do not provide new information regarding the company's operational performance or strategic direction that would warrant a change in investment recommendation. Investors should hold their positions and monitor future company-specific news and broader market trends.

Keywords

Pacira BioSciences, PCRX, Insider Trading, Form 4, Stock Sale, Kristen Williams, Chief Administrative Officer, 10b5-1 Plan, Restricted Stock Units, Tax Withholding